Bionano Genomics reports preliminary Q4 revenue $8.1-8.4M, up 27-33% YoY

Bionano Genomics, Inc.

2022-FY EPS reported -$0.46 revenue$27,802,000

Full-year 2022 revenue expected $27.7-28.0M, up 54-56% vs 2021; exceeded initial guidance ranges.
Installed base of Saphyr systems reached 240 at year-end, a 46% increase over 2021.
Completed acquisition of Purigen Biosystems to accelerate OGM adoption via improved DNA prep.
Planned commercial launch of next-gen OGM system in H1 2023; NxClinical v7.0 release also expected H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bionano Genomics, Inc. reported the year ended December 31, 2022 results: revenue $27.7 million and $28.0 million.

Period: the year ended December 31, 2022
Revenue: $27.7 million and $28.0 million
Result: preliminary results

Exact text from the filing

Full year 2022 revenue is expected to be in the range of $27.7 million and $28.0 million, an estimated increase of between 54% and 56% compared to 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bionano Genomics, Inc. reported the fourth quarter of 2022 results: revenue $8.1 million to $8.4 million.

Period: the fourth quarter of 2022
Revenue: $8.1 million to $8.4 million
Result: preliminary results

Exact text from the filing

Revenues for the fourth quarter 2022 are expected to be in the range of $8.1 million to $8.4 million , an estimated increase of 12% to 16% compared to $7.2 million in the third quarter of 2022 and an estimated increase of 27% to 33% compared to the fourth quarter of 2021.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-000651

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.